A detailed history of Vanguard Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,545,758 shares of KROS stock, worth $70.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,545,758
Previous 1,432,195 7.93%
Holding current value
$70.6 Million
Previous $56.9 Million 79.7%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$41.26 - $70.48 $4.69 Million - $8 Million
113,563 Added 7.93%
1,545,758 $102 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $698,719 - $1.06 Million
25,764 Added 1.83%
1,432,195 $56.9 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $7.03 Million - $9.58 Million
222,652 Added 18.81%
1,406,431 $44.8 Million
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $5.06 Million - $6.92 Million
135,717 Added 12.95%
1,183,779 $47.6 Million
Q1 2023

May 15, 2023

BUY
$41.44 - $59.32 $113,628 - $162,655
2,742 Added 0.26%
1,048,062 $44.8 Million
Q4 2022

Feb 10, 2023

BUY
$39.45 - $51.77 $5.47 Million - $7.18 Million
138,746 Added 15.3%
1,045,320 $50.2 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $3.75 Million - $5.41 Million
134,956 Added 17.49%
906,574 $34.1 Million
Q2 2022

Aug 12, 2022

BUY
$26.03 - $67.04 $911,700 - $2.35 Million
35,025 Added 4.76%
771,618 $21.3 Million
Q1 2022

May 13, 2022

BUY
$42.12 - $59.36 $121,010 - $170,541
2,873 Added 0.39%
736,593 $40.1 Million
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $885,285 - $1.51 Million
23,959 Added 3.38%
733,720 $42.9 Million
Q3 2021

Nov 12, 2021

BUY
$29.27 - $43.71 $1.22 Million - $1.82 Million
41,558 Added 6.22%
709,761 $28.1 Million
Q2 2021

Aug 13, 2021

BUY
$42.4 - $70.11 $28.3 Million - $46.8 Million
668,203 New
668,203 $28.4 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.